TACSTD2 and endometrioid adenocarcinoma: We found that among these targets, B7-H4, TROP2 and CD74 are upregulated considerably in endometrioid compared to serous cancer; there is no significant difference in the expression of CD71, MUC1, and CD138 between endometrioid and serous; the expression of ERBB3, FOLR1, and NaPi2b is higher in serous than in endometrioid carcinoma.